Nanocomposite scaffolds in spinal fusion surgery: toward enhanced osteointegration and reduced inflammation

Spinal fusion surgery often fails when bone graft substitutes cannot achieve robust osteointegration or provoke inflammation. Nanocomposite scaffolds such as hybrid biomaterials combining polymers, bioceramics, and nanofillers are emerging solutions. By mimicking bone's extracellular matrix and releasing bioactive ions or growth factors, these scaffolds significantly boost new bone formation. Recent preclinical studies in diverse settings report much higher fusion rates using nanocomposite scaffolds. For example, magnesium-doped hydroxyapatite/collagen scaffolds supplemented with platelet-rich plasma achieved solid fusion in 75% of treated animals versus 12.5% controls. Similarly, rat models in Japan showed 91.6% fusion using nano-hydroxyapatite/polymer scaffolds with low-dose BMP-2. These innovations not only promote osteoblast differentiation and angiogenesis but also allow incorporation of anti-inflammatory components (e.g., cerium oxide or silver nanoparticles) to mitigate post-surgical immune reactions. As international research groups in China, Japan, Iran, and elsewhere advance these materials, ongoing emphasis on standardized reporting and transparency is crucial. Our analysis underscores that nanocomposite scaffolds can bridge nanotechnology with clinical spinal reconstructive practice, justifying further clinical translation.